Eli Lilly reported second-quarter 2026 results on Wednesday, August 5, 2026, and the official release moved the story from a high-expectation setup into a real live-results phase. Lilly said Q2 revenue rose 48% year over year to USD 23.0 billion, reported EPS rose to USD 7.94, non-GAAP EPS rose to USD 8.38, and full-year 2026 revenue guidance increased to USD 85 billion to USD 87 billion. The same release also said volume rose 60% while realized prices fell 13%, which keeps the core post-earnings question focused on whether obesity-drug demand is still strong enough to outrun pricing pressure and justify another premium reset.
Those facts matter because the site already had a pre-event Lilly piece about what the market might price into August 5. That earlier LLY setup article was about expectations. The August 5 release changes the job for options traders. The question is no longer whether Lilly still had a powerful growth story. The question is whether the actual quarter, the raised guidance, and the mix between volume and pricing were strong enough to keep the stock’s valuation debate moving in Lilly’s favor after event premium comes out.
This article is for market commentary and options education only. This is not financial advice. Options trading involves risk and is not suitable for all investors. Review the site’s risk disclosure, the guide to how earnings affect options prices and implied volatility, the explainer on implied volatility (IV) in options trading: what it is and why it matters, and the guide to options volume versus open interest.
What Lilly actually reported
The most important confirmed facts from Lilly’s August 5, 2026 results materials were:
- Q2 2026 worldwide revenue was USD 23.0 billion, up 48% year over year.
- Volume rose 60% year over year, partially offset by a 13% decline in realized prices.
- Reported EPS was USD 7.94.
- Non-GAAP EPS was USD 8.38.
- Q2 2026 reported and non-GAAP EPS both included USD 3.03 of acquired IPR&D charges, versus USD 0.14 in Q2 2025.
- Key Products revenue reached USD 15.7 billion, led by Mounjaro and Zepbound.
- U.S. revenue rose 33% to USD 14.4 billion.
- Revenue outside the U.S. rose 80% to USD 8.6 billion.
- Gross margin rose 50% to USD 19.7 billion, and gross margin as a percent of revenue improved to 85.8%.
- Lilly raised full-year 2026 revenue guidance to USD 85 billion to USD 87 billion.
- Lilly’s Q2 release also said Foundayo was added to the company’s Key Products group in Q2 2026.
Those details matter because they show a quarter that was clearly strong, but not simple. Lilly delivered another large step higher in revenue and kept the obesity story moving through Mounjaro, Zepbound, and now Foundayo. At the same time, the release also said realized prices still moved lower, which means the options lesson remains about growth quality and durability, not just about a headline beat.
Why this is a distinct event phase
This is not the same lesson as the August 2 setup article. Before the release, the useful question was whether Lilly could satisfy a market that already had a demanding baseline. After results, traders can compare the actual print against that earlier bar directly:
- Lilly’s Q1 2026 revenue had been USD 19.8 billion.
- Lilly’s Q1 release had raised 2026 revenue guidance to USD 82 billion to USD 85 billion.
- Lilly’s August 5 release reported Q2 revenue of USD 23.0 billion.
- Lilly’s August 5 release raised 2026 revenue guidance again, this time to USD 85 billion to USD 87 billion.
- Lilly’s Q1 materials had already warned that lower realized prices were offsetting part of the volume surge.
- Lilly’s Q2 materials repeated that same tension, with volume up 60% and realized prices down 13%.
That is a real phase change. The market no longer has to guess whether Lilly would raise the bar again. It now has to decide whether the new bar is strong enough to support another repricing in one of the market’s most closely watched large-cap healthcare names.
Why It Matters For Options Traders
1. Lilly raised the full-year bar again
The cleanest bullish fact in the release is not only the 48% revenue growth. It is that Lilly raised full-year 2026 revenue guidance from USD 82 billion to USD 85 billion up to USD 85 billion to USD 87 billion. That matters because options traders are often trying to judge whether a quarter changed the forward earnings-power frame or merely confirmed what investors already expected.
In Lilly’s case, another revenue-guidance raise tells the market that management still sees enough demand and operating momentum to move the full-year target higher even after an already huge first quarter. That can matter more for repricing than a one-quarter beat by itself.
2. Volume is still outrunning price pressure, but the price debate is not gone
Lilly again showed the same mix that made the setup article relevant in the first place: massive volume growth and lower realized prices at the same time. Volume rose 60%, but realized prices fell 13%. In the U.S., volume rose 37% while price declined 3%. Outside the U.S., volume rose 113% while price declined 36%.
That matters because options traders do not just need to know whether the business is growing. They need to know what kind of growth the market is being asked to value. If investors decide the volume engine is still comfortably outrunning pricing pressure, the post-earnings reset can stay constructive. If investors decide lower prices are becoming the bigger story, the same strong quarter can still produce a more mixed stock reaction than the headline numbers suggest.
3. EPS quality still needs interpretation
Lilly’s reported EPS and non-GAAP EPS were both strong, but the company also said both figures included USD 3.03 of acquired IPR&D charges. That does not make the quarter weak. It means traders should be careful about treating a single EPS line as the whole story.
For options readers, the practical lesson is straightforward: the market may care more about revenue quality, gross margin, product mix, and raised guidance than about any one EPS comparison on its own. A stock can report a powerful quarter and still see the post-event debate revolve around how durable the clean operating read really was.
4. Lilly is becoming harder to frame as a one-product story
Mounjaro and Zepbound remain the core growth engine, but Lilly also used the Q2 release to include Foundayo in its Key Products group. That matters because the market is no longer only evaluating one injectable obesity or diabetes franchise. It is evaluating whether Lilly can keep broadening the platform while scaling manufacturing, defending mix, and sustaining growth across multiple therapeutic areas.
For options traders, that means the stock can keep behaving like a multi-variable earnings name even after the calendar event has passed. The next repricing is not only about one quarter’s demand. It is about whether the market sees a broader and more durable growth machine than it had before.
Common misunderstandings and caveats
Revenue up 48% means the stock must keep rallying
No. Strong growth helps, but a post-earnings move still depends on what was already priced in, how investors read the quality of the quarter, and how much of the guidance raise the market now treats as durable.
More obesity-drug volume means pricing no longer matters
No. Lilly’s own release still showed lower realized prices. Volume and pricing are moving in opposite directions, and the balance between them remains one of the main things the market has to judge.
EPS alone tells the whole story
No. Lilly said both reported and non-GAAP EPS included significant acquired IPR&D charges in the quarter. That makes the broader operating and guidance picture more useful than a one-line EPS reaction.
Options pricing reveals direction
No. Options pricing reflects uncertainty, hedging demand, time to the catalyst, and positioning. It does not provide a clean directional forecast for what LLY must do after earnings.
Bottom line
Lilly turned Wednesday, August 5, 2026 into a genuine live-results phase for options traders. Revenue rose to USD 23.0 billion, reported EPS reached USD 7.94, non-GAAP EPS reached USD 8.38, and full-year 2026 revenue guidance moved up to USD 85 billion to USD 87 billion.
For options traders, the useful takeaway is not simply that Lilly had another huge quarter. The useful takeaway is that the company raised the forward bar again while still showing the same tension between extraordinary volume growth and lower realized prices. The post-event repricing now depends on whether the market treats that combination as proof that Lilly’s obesity platform can keep supporting a premium valuation, or as a sign that future upside still has to outrun an increasingly visible pricing debate. This is not financial advice.
Sources
- Eli Lilly Investor Relations, “Lilly reports second-quarter 2026 financial results, raises full-year revenue guidance” (plain-text URL):
https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2026-financial-results-raises-full - Eli Lilly Q2 2026 earnings-release PDF (plain-text URL):
https://investor.lilly.com/node/54781/pdf - Eli Lilly Q1 2026 earnings-release PDF (plain-text URL):
https://investor.lilly.com/node/54176/pdf - Eli Lilly Investor Relations, “FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for obesity management” (plain-text URL):
https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
